

Operationalizing Addiction Screening and Treatment

May 29, 2020

Tipu V. Khan, MD, FAAFP, FASAM

Medical Director, Prototypes/Health Right 360 Southern
California; Fellowship Director, VCMC ADMF Program

Disclosure


- Dr. Khan serves as a speaker for AbbVie on Hepatitis C Treatment.
- Planners have no financial conflicts to disclose.

Learning Objectives

After this webinar, participants will be able to:

1. Discuss strategies for integrating and operationalizing substance use disorder screening in a family planning and primary care setting.
2. Identify barriers and opportunities for integrating and operationalizing the provision of Medication Assisted Treatment.
3. Initiate a focused project to improve their delivery of substance use disorder treatment.

Road Map



Poll #1

1. Please select where you are in the process of MAT in your system:
 - a. Preparation
 - b. Screening
 - c. Implementation
 - d. Not sure if you are providing MAT at your site
 - e. No current plans to provide MAT at this time
 - f. N/A

Preparation Phase


Begin assessing clinical need and reach out to community partners and other stakeholders to get buy in.

Explore

- Build an implementation team
 - Prescribing Provider Champion
 - Clinic Manager
 - Medical Director
- Identify Goals
 - When?
 - How?
 - Different models
 - Where?
- Conduct a needs assessment
- Identify potential solutions

Regional Hub and Spoke Model

- Project Echo
 - **A**: Amplification – Use technology to leverage scarce resources
 - **B**: Share **B**est practices to reduce disparity
 - **C**: **C**ase-based learning to master complexity
 - **D**: Web-based **D**atabase to monitor outcomes



Clinical Hub and Spoke Model

- Opioid Treatment Program or Specialist Partnership
 - They induce/stabilize
 - PCP takes over maintenance
- Internal Referrals
 - Group refers to internal X-waivered providers to treat ONLY the SUD
- External Referrals
 - Clinic partners with other local providers to provide MAT

Outreach

- Identify referral sources
 - Emergency Departments
 - Urgent Care
 - SAMHSA Buprenorphine Treatment Practitioner Locator
 - Local providers/clinics
 - Internal referrals
- Start low, go slow!

Staff

- Provide stigma training to staff
 - <https://pcssnow.org/education-training/training-courses/stigma-and-oud/>
- Team approach
 - Front office/Receptionist
 - Back office: MA, RN
 - Providers
 - Counselors
 - **Champion!**

Prescriber

- Identify at least 2 X-waivered providers
- Identify Prescriber Champion
- Home and In-office Induction process
- Consider Hub and Spoke programs
- Decide scheduling type
 - Integrated
 - Dedicated

Poll #2

1. How many x-waivered providers are in your system?
 - a. 0
 - b. 1
 - c. 2-3
 - d. 4-6
 - e. 7-10
 - f. 10+
 - g. N/A

Scheduling Models

- **Integrated**
 - Benefits: Normalizes SUD as a chronic disease, allows for a diverse patient panel, increased access for the patient.
 - Downsides: Requires all staff be trained on policies/procedures, requires all team members be available.
- **Dedicated**
 - Benefits: Easier to coordinate all team members be available, can train staff to be experts and may increase workflow.
 - Downsides: Stigmatizes MAT as separate from primary care, availability is more limited.

Poll #3

1. Which model do you see working best in your system?
 - a. Integrated
 - b. Dedicated
 - c. N/A

Billing and Prior Auth/TARs

- Determine which insurances you will take
- Self Pay
- Medicaid is a large group
- Determine what PA/TAR process will be



Policy and Procedures

- Record keeping
- Provider coverage (vacation, after hours)
- Patient management checklist and flow
- Screening process
- Induction process
- Maintenance process

Documentation

- Ensure standards are uniform across all providers
- Consider templated notes
 - Initial visit
 - Induction
 - Follow Up

Treatment Agreement

- Trial
- Pharmacy
- Medication
- Refill policy
- Avoidance of CNS depressants
- Adverse Effects

Prescriptions

- Identify and contact preferred pharmacy to ensure they stock your medication and dosages
- Consider local pharmacist owned pharmacies
- Is the pharmacy easily accessible?
- Are the inviting and receptive of this patient population?

Patient Tracking

- EMR Reports
 - ICD 10 codes
 - Prescriptions
 - Naloxone Rx
- Consider separate records for MAT patients

Screening

Implement evidence based screening that is universal and trauma informed.

Screening

- Choose a validated tool that works best for your clinical practice and time availability
- What are you looking for?
 - Drugs VS Alcohol
- Who are you screening?
 - Age
 - Special populations
- Who does the screening?
 - Patient self administered VS staff administered
- Remember to bill

NIDA

Tool	Substance type		Patient age		How tool is administered	
	Alcohol	Drugs	Adults	Adolescents	Self-administered	Clinician-administered
Screens						
Screening to Brief Intervention (S2BI)	X	X		X	X	X
Brief Screener for Alcohol, Tobacco, and other Drugs (BSTAD)	X	X		X	X	X
Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS)	X	X	X		X	X
NIDA Drug Use Screening Tool: Quick Screen (NMASSIST)	X	X	X	See APA Adapted NM ASSIST tools	See APA Adapted NM ASSIST tools	X
Alcohol Use Disorders Identification Test-C (AUDIT-C (PDF, 41KB))	X		X		X	X
Alcohol Use Disorders Identification Test (AUDIT (PDF, 233KB))	X		X			X
Opioid Risk Tool (PDF, 168KB)		X	X		X	
CAGE-AID (PDF, 30KB)	X	X	X			X
CAGE (PDF, 14KB)	X		X			X
Helping Patients Who Drink Too Much: A Clinician's Guide (NIAAA)	X		X			X
Alcohol Screening and Brief Intervention for Youth: A Practitioner's Guide (NIAAA)	X			X		X

Implementation

Provide high quality MAT with appropriate stop gaps and safety checks to keep everyone safe and satisfied.

Front Office

- Create a receptive environment for those calling in
 - Remember, first impression is everything and these patients are often apprehensive of the medical system
- Be flexible with scheduling
 - Getting an IV Drug using patient off opiates is a priority to prevent overdose deaths and can not wait for the next available appointment in 4 weeks

Back Office

- MA to measure COWS on intake
 - Teach staff how to use a COWS (Clinical Opiate Withdrawal Scale)
- Collect urine
 - To send or not to send, that is the question.
 - Initial
 - Follow up
- Run PDMP Cures
 - Set up a delegate to help prepare the days reports
 - Health and Safety Code Section 11165.4
 - Before Rx for the first time AND
 - At least q4 months if maintenance

Provider

- Obtain H+P
- Determine DSM-V Diagnosis of SUD
- Initiate MAT
 - Be aware of prior authorization or TAR requirements
- Schedule close follow up
- Document plan
- Coordinate psychosocial referrals

DSM 5 - OUD

Opioid Use Disorders – DSM V

13

The diagnosis of Opioid Use Disorder under DSM V can be applied to someone who uses opioid drugs and has at least two of the following symptoms within a 12 month period:


- Taking more opioid drugs than intended.
- Wanting or trying to control opioid drug use without success.
- Spending a lot of time obtaining, taking, or recovering from the effects of opioid drugs.
- Cravings opioids.
- Failing to carry out important roles at home, work or school because of opioid use.
- Continuing to use opioids, despite use of the drug causing relationship or social problems.
- Giving up or reducing other activities because of opioid use.
- Using opioids even when it is physically unsafe.
- Knowing that opioid use is causing a physical or psychological problem, but continuing to take the drug anyway.
- Tolerance for opioids.
- Withdrawal symptoms when opioids are not taken.



Special Populations

- Identify which patients require expert consultation
 - Pregnant
 - Adolescents
 - Geriatrics
 - Poly-Substance
 - Other CNS depressant meds/drugs
 - Severe dual-diagnosis
- UCSF SUD Warm Line 0900-2000 ET
 - 855-300-3595

Appointment Flow




Intake Appointment

- Counsel patient on
 - Risks/Benefits/Alternatives
 - Home vs in-office induction
 - Psychosocial support and treatment
- Sign treatment consent
- Review PDMP and provide Rx
- Labs
 - UDS
 - LFTs
 - Hepatitis Panel (and consider vaccinating)
 - Pregnancy test


Induction Visit

- Home Induction
 - Provider home induction instructions
 - Schedule phone/clinic follow up on day 3
 - Schedule follow up at week 1
- In-office induction
 - Provide instructions for last use
 - Schedule induction visit
 - Anticipate up to 2 hours
 - Schedule follow up visit/call on day 3
 - Schedule follow up at week 1

Office Induction



Home Induction



Monitoring

- PDMP Reports
- UDS
- Med counts
- Once stable, consider 3 month appointments

Naloxone

It's the law → AB 2760

- MEQ 90 or more
- Opioid + BZD
- Inc risk of OD
 - h/o OD
 - h/o SUD
- Increasing tolerance

Overdose is the leading cause of injury-related death in the U.S.

100 PEOPLE DIE FROM DRUG OVERDOSE EVERYDAY IN THE UNITED STATES.

FIGURE 1. DEATH BY LEADING CAUSE OF INJURY (PER 100,000)¹





FIGURE 2. OVERDOSE DEATH BY DRUG TYPE²



Opioid analgesics accounted for over 16,000 deaths in 2010.

Poll #4

1. Are you are routinely prescribing naloxone per California guidelines?
 - a. Yes
 - b. No
 - c. N/A

Resources

- Provider Clinical Support System (PCSS): <https://pcssnow.org/>
- Project Echo: <https://echo.unm.edu/opioid-focused-echo-programs/>

Center of Excellence for Integrated Health Solutions



Jeff Richardson, MBA, LCSW-C, Board Chair
Charles Ingolia, MSW, President and CEO

Organizational Readiness

Critical to the successful implementation of any new initiative is the organization's readiness to take on such an initiative. When implementing MAT services, organizations must have significant administrative support and clear organizational processes in place.

Question/Area of Consideration	Not Ready	In progress	Ready
Does your organizational leadership, including your board of directors, support the use of MAT? <ul style="list-style-type: none"> • Could they benefit from gaining further information about MAT? • Are there opportunities for sharing this information with your organization's board? 			
Do you have data that demonstrate the potential benefits of offering MAT to the people you serve, including information on comorbid conditions and medication use?			
Have you decided what MAT services you will offer? <ul style="list-style-type: none"> • Opioid use disorder • Alcohol use disorder • Smoking cessation 			
Have you decided who you will offer services to? <ul style="list-style-type: none"> • All patients • Those with comorbid mental health disorders (see example below) • Those with comorbid chronic medical conditions • Other 			
Do you have a plan to provide or connect patients to appropriate counseling and other behavioral health services?			
How will you implement the most current guidelines for the use of MAT?			
Do you have a quality assurance protocol for supporting and maintaining these new practices?			
Does your infrastructure support requirements (e.g., appropriate clinical space, storage) for offering MAT services?			
Do you know how 42CFR or state-based confidentiality laws would apply to your organization and patient populations?			

Copyright: National Council for Behavioral Health. May not be reproduced in whole or part without express permission. Contact Communications@thenationalcouncil.org or 202.684.7457



<https://www.thenationalcouncil.org/integrated-health-coe/resources/>

Boston Medical Center OBAT



The screenshot shows the top portion of the OBAT TTA website. On the left is the logo for OBAT TTA, which includes a stylized graphic of two figures and the text "OBAT TTA | Office Based Addiction Treatment Training and Technical Assistance". To the right of the logo are links for "LOGIN" and "CREATE ACCOUNT". Below the logo is the tagline "A Resource for Healthcare and Social Services Professionals". A dark purple navigation bar contains the following items: "Home", "Get TTA" (with a dropdown arrow), "Our TTA Services" (with a dropdown arrow), "Project ECHO®" (with a dropdown arrow), "Resources" (with a dropdown arrow), "News", and "About Us" (with a dropdown arrow). Below the navigation bar is an orange banner with the text "Click Here for COVID-19 Resources".

RESOURCES

Select a category

- [Addiction Education and Training Resources](#)
- [Clinical Algorithms](#)
- [COVID-19](#)
- [OBAT Clinical Guidelines](#)
- [OBAT Clinical Tools and Forms](#)
- [Opioid Use Disorder Education Program – Free Continuing Education](#)
- [Patient and Family Resources](#)
- [Provider Resources](#)
- [Resources for Waiver Training Courses](#)
- [Videos from Our Experts](#)

Questions

For continuing education credit, you must complete the post assessment evaluation and continuing education form. Click 'Continue' to open the survey when you log out of the webinar. An email with a link to the survey will also be sent to attendees after the session.

Upcoming Events



Free COVID-19 Webinar Series

Delivering Sexual Health Services in the Time of COVID-19
June 11, 2020 - 12:00 PM - 1:30 PM

Medication-Assisted Treatment for Substance Use Disorder in a Family Planning or Primary Care Setting Free Webinar Series

Webinar 4: Problem Solving + Overcoming Challenges with Addiction
Screening + Treatment
June 24, 2020 - 12:00 PM- 1:00 PM

Register at essentialaccesstraining.org for these and other Online Courses and
On-Demand Webinars via our Learning Portal

Questions? Contact us at learningexchange@essentialaccess.org